Cargando…
Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474870/ https://www.ncbi.nlm.nih.gov/pubmed/34627005 http://dx.doi.org/10.1016/j.msard.2021.103287 |
| _version_ | 1784575317019459584 |
|---|---|
| author | Sahi, Nitin Kumar Abidi, Syed Muhammad Ali Salim, Omar Abraham, Roby Kalra, Seema Al-Araji, Adnan |
| author_facet | Sahi, Nitin Kumar Abidi, Syed Muhammad Ali Salim, Omar Abraham, Roby Kalra, Seema Al-Araji, Adnan |
| author_sort | Sahi, Nitin Kumar |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8474870 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84748702021-09-28 Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation Sahi, Nitin Kumar Abidi, Syed Muhammad Ali Salim, Omar Abraham, Roby Kalra, Seema Al-Araji, Adnan Mult Scler Relat Disord Article Elsevier B.V. 2021-11 2021-09-27 /pmc/articles/PMC8474870/ /pubmed/34627005 http://dx.doi.org/10.1016/j.msard.2021.103287 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Sahi, Nitin Kumar Abidi, Syed Muhammad Ali Salim, Omar Abraham, Roby Kalra, Seema Al-Araji, Adnan Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation |
| title | Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation |
| title_full | Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation |
| title_fullStr | Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation |
| title_full_unstemmed | Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation |
| title_short | Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation |
| title_sort | clinical impact of ocrelizumab extended interval dosing during the covid-19 pandemic and associations with cd19(+)b-cell repopulation |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474870/ https://www.ncbi.nlm.nih.gov/pubmed/34627005 http://dx.doi.org/10.1016/j.msard.2021.103287 |
| work_keys_str_mv | AT sahinitinkumar clinicalimpactofocrelizumabextendedintervaldosingduringthecovid19pandemicandassociationswithcd19bcellrepopulation AT abidisyedmuhammadali clinicalimpactofocrelizumabextendedintervaldosingduringthecovid19pandemicandassociationswithcd19bcellrepopulation AT salimomar clinicalimpactofocrelizumabextendedintervaldosingduringthecovid19pandemicandassociationswithcd19bcellrepopulation AT abrahamroby clinicalimpactofocrelizumabextendedintervaldosingduringthecovid19pandemicandassociationswithcd19bcellrepopulation AT kalraseema clinicalimpactofocrelizumabextendedintervaldosingduringthecovid19pandemicandassociationswithcd19bcellrepopulation AT alarajiadnan clinicalimpactofocrelizumabextendedintervaldosingduringthecovid19pandemicandassociationswithcd19bcellrepopulation |